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Abstract
There has been considerable investigation of the potential for soyfoods to reduce risk of cancer,
and in particular cancer of the breast. Most interest in this relationship is because soyfoods are
essentially a unique dietary source of isoflavones, compounds which bind to estrogen receptors and
exhibit weak estrogen-like effects under certain experimental conditions. In recent years the
relationship between soyfoods and breast cancer has become controversial because of concerns –
based mostly on in vitro and rodent data – that isoflavones may stimulate the growth of existing
estrogen-sensitive breast tumors. This controversy carries considerable public health significance
because of the increasing popularity of soyfoods and the commercial availability of isoflavone
supplements. In this analysis and commentary we attempt to outline current concerns regarding
the estrogen-like effects of isoflavones in the breast focusing primarily on the clinical trial data and
place these concerns in the context of recent evidence regarding estrogen therapy use in
postmenopausal women. Overall, there is little clinical evidence to suggest that isoflavones will
increase breast cancer risk in healthy women or worsen the prognosis of breast cancer patients.
Although relatively limited research has been conducted, and the clinical trials often involved small
numbers of subjects, there is no evidence that isoflavone intake increases breast tissue density in
pre- or postmenopausal women or increases breast cell proliferation in postmenopausal women
with or without a history of breast cancer. The epidemiologic data are generally consistent with
the clinical data, showing no indication of increased risk. Furthermore, these clinical and
epidemiologic data are consistent with what appears to be a low overall breast cancer risk
associated with pharmacologic unopposed estrogen exposure in postmenopausal women. While
more research is required to definitively allay concerns, the existing data should provide some
degree of assurance that isoflavone exposure at levels consistent with historical Asian soyfood
intake does not result in adverse stimulatory effects on breast tissue.
Background
In 1990, participants of a workshop sponsored by the U.S.
National Cancer Institute concluded that soybeans con-
tain several putative chemopreventive agents [1]. In the
years since, there has been considerable investigation of
the potential for soyfoods to reduce risk of cancer, and in
particular cancer of the breast. The basis for the initial
focus on breast cancer can be attributed to several things:
the historically low breast cancer incidence rates in Asia,
where soyfoods comprise an important dietary compo-
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nent [2]; research demonstrating the potential for isofla-
vones – one of the putative chemopreventive agents
identified in soybeans – to exert antiestrogenic effects [3];
early epidemiologic data showing an inverse association
between soy intake and breast cancer risk [4]; and rodent
studies showing a protective effect of soy intake against
carcinogen-induced mammary cancer [5].
In recent years, however, the relationship between soy-
foods and breast cancer has become controversial because
of concerns that soy-derived isoflavones, which exhibit
estrogen-like properties under certain experimental con-
ditions, may stimulate the growth of existing estrogen-
sensitive breast tumors [6]. These concerns exist because
of evidence showing that isoflavones bind and transacti-
vate estrogen receptors (ERs) [7,8], induce proliferation
and estrogenic markers in MCF-7 cells, an ER positive
(ER+) breast cancer cell line [9-14], and elicit estrogenic
effects in rodent reproductive tissues [15,16]. In contrast
to these findings, epidemiologic evidence shows that
among Asian women, higher soy intake is associated with
a nearly one-third reduction in breast cancer risk [17] and
that Japanese breast cancer patients, in comparison to
Western women, exhibit better survival rates even after
controlling for stage of diagnosis [18-22].
In 2006, the American Cancer Society concluded that
breast cancer patients can safely consume up to three serv-
ings of traditional soyfoods per day, although the group
advised against the use of more concentrated sources of
isoflavones such as powders and supplements [23]. Other
expert views are less supportive of the use of any isofla-
vone-containing products for breast cancer survivors and
in some cases for women at high risk of this disease [24-
28]. Many women are understandably confused about
whether to incorporate soy into their diet. Thus, there is a
need for health professionals to have a better understand-
ing of the current evidence relating to soy and breast can-
cer so that they can better advise their patients and clients.
In this analysis and commentary we attempt to outline
current concerns regarding estrogen-like effects of isofla-
vones in the breast and place these concerns in context of
recent evidence regarding estrogen therapy (ET) use in
postmenopausal women.
Background on isoflavones
The three soybean isoflavones are genistein, daidzein, and
glycitein. These non-steroidal compounds are naturally
present in the soybean and non-fermented soyfoods pri-
marily in their beta glycoside forms: genistin, daidzin, and
glycitin. Throughout this paper isoflavone amounts refer
to the aglycone weight, which is ~60% of the glycoside. In
the soybean itself and in most soy products, genistin/gen-
istein, daidzin/daidzein, and glycitin/glycitein account for
approximately 50–55%, 40–45%, and 5–10% of total iso-
flavone content, respectively [29]. Older adults in Japan
and Shanghai, China, typically consume between 25 and
50 mg/d isoflavones and probably no more than 5% of
these populations consume ≥ 100 mg/d [30]. In contrast,
people in the United States and Europe consume on aver-
age < 3 mg/d of isoflavones [31-33].
Isoflavones are diphenolic compounds with a chemical
structure similar to estrogen that bind to both estrogen
receptors alpha (ERα) and beta (ERβ) and, for this reason,
are commonly referred to as phytoestrogens [34,35]. Iso-
flavones exhibit estrogen-like properties but bind more
weakly to ERs than 17β-estradiol (E2), which is the pri-
mary physiologic estrogen. Genistein, which is the main
circulating and best-studied isoflavone, transactivates ERα
and induces estrogenic effects with ~103-104 less potency
than E2 [7,8]. However, serum isoflavone concentrations
after a high-soy meal can reach low micromolar levels
[36,37], thereby exceeding postmenopausal total estrogen
concentrations by ~103 [38]. This evidence has contrib-
uted to the idea that isoflavones may potentially elicit
estrogen-like effects and thus serve as a natural alternative
to ET in postmenopausal women. Isoflavones also prefer-
entially bind to and transactivate ERβ in comparison to
ERα [9,39,40] and induce distinct changes in ER confor-
mation [41], leading to speculation that they may func-
tion as selective estrogen receptor modulators (SERMs)
[42-44]. Despite this designation, unlike different forms
of estrogen [45-55], there is scant evidence for any clear
estrogen-like or antiestrogenic-like effects of soyfood or
isoflavone intake on the human breast or a number of
other parameters [44,55-64].
Effects of isoflavones on mammary/breast cell 
proliferation
Animal studies
Concern over the possible tumor-stimulatory effects of
isoflavones is based largely on the proliferative effect of
genistein on MCF-7 cells in vitro and in studies of mam-
mary cancer in rodents. A variety of studies have shown
that isoflavones stimulate ER+ human breast cancer cell
xenoplants in ovariectomized athymic mice [13,65-68],
estrogen-dependent mammary tumors in rats [69], and
reproductive tissues in adult female mice [70,71]. Other
research using rodent models has also demonstrated that
genistein is the primary isoflavone responsible for tumor
stimulation [72]; that more processed soy products result
in faster tumor growth than less processed soy products
[68]; and that genistein inhibits the efficacy of tamoxifen,
a SERM used in the treatment and prevention of breast
cancer [73].
Even in rodent models, however, isoflavones are generally
weak estrogen agonists relative to E2. Most rodent studies
use scaled doses at least 5 times the amount found in tra-Nutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
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ditional Asian diets [30], and many studies have used
direct injection of purified isoflavones, which results in
substantially higher levels of unconjugated isoflavones
than dietary administration [70]. Importantly, the isofla-
vone dose required for estrogen-like effects in women has
yet to be identified despite three decades of study. So
although isoflavones clearly act as estrogens in rodent
models, relevant dose effects for human consumption are
still very unclear.
There are several noteworthy limitations/weaknesses of
the ovariectomized athymic mouse models used in many
of the experiments noted above. First, the lack of immune
function, which is a necessary element of these models,
may eliminate a potential mechanism by which genistein
reduces tumor development. Recent research in B6C3F1
mice shows that enhanced immune function resulting
from pretreatment with genistein (20 ppm) is correlated
with protection against chemically-induced mammary
tumors [74]. Second, unlike postmenopausal women,
ovariectomized mice do not produce sufficient endog-
enous estrogen to promote development and growth of
estrogen-dependent tumors. Thus, the effects of isofla-
vones are occurring in an estrogen-depleted environment
that does not accurately reflect conditions in either pre-
menopausal or postmenopausal women. It has been
argued that estrogenic and tumor-stimulatory effects of
isoflavones may be evident only in this type of hypoestro-
genic environment. However, this criticism has been
addressed by two different models in which isoflavones
still lead to tumor stimulation. In one, mice are implanted
with MCF-7Ca  cells transfected with the enzyme aro-
matase, enabling the cells to synthesize estrogen; in the
other model, mice are continually given small amounts of
estrogen [75].
A third critique relates to isoflavone dose. In many studies
showing estrogenic effects, mice are exposed to an
amount of genistein (750 ppm) that greatly exceeds typi-
cal dietary intake. In Japan for example, adults consume
about 15–20 mg genistein daily (total mean isoflavone
intake is approximately 40 mg), which equates to a dietary
concentration of about 30–40 ppm. When expressed on a
caloric basis to adjust for differences in metabolism, the
difference between human and rodent isoflavone expo-
sure is ~8–16 times higher than the 25 – 50 mg per 1800
Kcal in a traditional Asian diet. (A 30 gm mouse consum-
ing 3 gm of food/d with 750 ppm genistein will consume
~2.25 mg/d of isoflavones, which equates to ~405 mg per
1800 Kcal.) Exposure to purified genistein levels as low as
150 ppm has also been shown to stimulate MCF-7 cell
growth, albeit to a lesser extent than higher genistein
doses or E2 treatment [67]. Fourth, it is not clear to what
extent the existing MCF-7 xenoplants in nude mice reflect
tumors in breast cancer patients. These tumors are fully
transformed and composed of cells that are extremely sen-
sitive to the growth-stimulating effects of estrogen.
Finally, other potentially relevant rodent models [76-78]
have shown that isoflavones or isolated soy protein (ISP,
by definition is >90% protein) suppress, rather than stim-
ulate, the growth of tumors in mice implanted with MCF-
7 cells and even enhance the efficacy of tamoxifen [79,80].
Clinical studies
Breast tissue is highly regulated by sex hormones, particu-
larly estrogens and progestogens, and breast epithelial
proliferation is widely used as an indicator of hormonal
exposure or effect. Epithelial cell proliferation also serves
as an important prognostic marker in human breast can-
cer [81] and may help predict risk associated with differ-
ent hormonal agents [82]. A common method for
evaluating proliferation is the immunohistochemical
marker Ki67 (also called MIB1), which is a nuclear protein
expressed by cells in all active phases of the cycle but not
in quiescent or resting cells [83]. Ki67 labeling correlates
significantly with higher carcinoma grade, clinical
response to endocrine therapy, higher risk of relapse, and
worse survival in patients with early breast cancer [84-87].
Four trials, two involving breast cancer patients [88,89],
one in healthy subjects [61], and one in women undergo-
ing breast biopsy or definitive surgery for breast cancer
[90] were identified in which breast biopsies were taken
before and after exposure to either isoflavone supple-
ments or ISP (Table 1). In no case did the intervention
lead to an increase in breast epithelial cell proliferation,
which was used in these studies as a marker of potential
tumor promotion. Daily isoflavone intake in these trials
ranged from 36 [61,91] to >100 mg [88,89] and study
duration from 2 weeks [90] to one year [89]. In compari-
son, postmenopausal ET results in modest variable
increases in proliferation, while estrogen plus progestin
therapy (EPT) results in more significant increases in
breast cell proliferation [92,93].
In one of the trials performed in healthy subjects, 28 post-
menopausal women consumed 60 g textured vegetable
(soy) protein containing 45 mg isoflavones for 2 weeks.
No statistically significant effects on cell proliferation or
several other estrogen-responsive markers were found,
including progesterone receptor expression, Bcl-expres-
sion, and cells undergoing apoptosis and mitosis. How-
ever, levels of the estrogen-regulated protein pS2
significantly increased subsequent to soy consumption
within breast nipple aspirate (NAF) [69]. The second trial
was a 12-week Swedish study in which 51 healthy post-
menopausal women took a daily placebo or a supplement
that provided 36 mg/d isoflavones [61]. No statistically
significant effects of isoflavone treatment were seen onNutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
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Table 1: Clinical effects of isoflavones and soy protein on markers of breast cancer risk
Author, 
Year/
(Reference)
Subject No./
Intervention 
Product/
Isoflavone 
Exposure 
(mg/d)1
Study Length Subject 
Description
Sampling 
Method
Primary 
Measures of 
Interest
Results
Breast Biopsies
Cheng, 2007/
(61)
25/placebo
26/tablets/36
12 wk Healthy post-
menopausal 
women, age 
range, 49–69 
y; mean age, 
~57
Middle-needle 
biopsy of 
breast tissue 
using 
ultrasound to 
identify 
glandular 
tissue
ERα, ERβ, 
ERβcx,2 and 
PRα/β3 
expression, 
Ki67
NSE5 for any measure. The proliferation marker, 
Ki67, was seen in 0% to 3% of samples, and no 
significant change was induced by isoflavone 
treatment.
Sartippour, 
2004/(88)
26/historical 
controls
17/tablets/
120
~22 d Women with 
invasive/
infiltrating 
breast cancer 
diagnosed by 
core-needle 
biopsy; mean 
age, ~61 y
Breast cancer 
biopsies and 
surgical 
specimens
ER & PR 
expression, 
p53, her-2/
neu, DNA 
flow analysis, 
apoptosis and 
mitosis
NSE but trend toward an ↑ in the ratio of cells 
undergoing apoptosis versus mitosis in isoflavone 
(IF) group
Apoptosis/Mitosis*
Control Isoflavone
Pre 6.5 ± 7.0 5.5 ± 4.7
Post 3.3 ± 3.4 5.8 ± 8.3
*Apoptosis and mitosis counts/high-power fields, 
means ± SD
Palomares, 
2004/(89)
9/placebo
9/tablets/100
11.7 mo Postmenopau
sal women 
previously 
diagnosed 
with in-situ or 
early stage 
invasive (Stage 
I-II) breast 
cancer; mean 
age, 56.9 ± 1.4 
y
Ultrasound-
guided 14-
gauge core 
biopsies of the 
contralateral 
breast
Histology, ER/
PR 
expression, 
Ki67
NSE for any measure.
Breast tissue 
histology*
PBO IF
Normal 5 5
Hyperplasia w/
o atypia
22
Hyperplasia 
with atypia
01
Inadequate 2 1
Ki67 index* 
(mean)
5.9% 5.4%
(SD) 5.2% 6.5%
* values represent number of subjects
Hargreaves, 
1999/(90)
53/UD5
28/UD + 60 g 
soy
protein/~45
14 d Premenopaus
al women 
undergoing 
breast biopsy 
or definitive 
surgery for 
breast 
cancer;6 mean 
age, ~33 y
Grossly 
normal breast 
tissue (~1 
cm3) excised 
at least 1 cm 
from the site 
of the lesion.
ER/PR 
expression, 
thymidine and 
Bcl-2 labeling, 
Ki67
NSE for any measure
Ki67 labeling index
Wks 1 & 2 Wks 3 & 4Nutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
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Control 3.16 ± 3.08 6.03 ± 4.27
Soy 4.76 ± 6.16 6.17 ± 7.0
Values are mean ± SD
Mammograms (Breast Tissue Density)
Tice (in 
press)/(98)7
23/UD+25 g 
casein
24/UD+25 g 
ISP8/50
6 mo Premenopaus
al women at 
high risk of 
breast cancer 
(defined by 
Gail risk ≥ 
1.67% and 
mammographi
c breast 
density ≥ 
50%)
Timed to late follicular phase 
(Day 10). Computer-aided 
contour method. Pre/post films 
read paired in random order at 
close of study, CC view and 
single reader
NSE
Powles, 
2008/(99)
Premenopaus
al
111/tablets/
409
111/Placebo/
0
Postmenopau
sal
8/tablets/409
11/placebo/0
3 y Healthy 
women aged 
between 35 
and 70 y with 
at least one 
first-degree 
relative with 
breast cancer
Mammograms were conducted 
on both breasts. All film images 
were digitalized and breast 
density was determined from 
the digital or digitalized images. 
Breast density was measured 
on a scale of 0–100 with higher 
figures representing more 
dense breasts
Mean change (%) from baseline plus 95% CI 
Premenopausal
Isoflavone 3.03 (-5.53 – -0.54)
Placebo 6.60 (-9.04 – -4.16)
Postmenopausa
Isoflavone -6.9 (-11.6 – -2.1)
Placebo -8.0 (-15.7 – -0.2)
Maskarinec, 
2004/(96)
103/UD
98/2 servings 
soyfoods/~50
~2.2 y Healthy 
premenopaus
al women; 
average age, 
~43 y
Computer-assisted density 
assessment. All mammograms 
for 1 woman were assessed 
during the same session, but 
the reader was unaware of the 
group status or the time 
sequence of the mammograms.
Breast tissue density (%)
Control Soy
Baseline 48.1 ± 25.2 45.6 ± 23.3
Final 43.2 ± 24.3 40.5 ± 23.7
Change 4.1 ± 10.2 2.8 ± 9.6
Values are means ± SD. NSE
Atkinson, 
2004/(97)
61/Placebo
56/tablets/
43.59
12 mo Postmenopau
sal women 
with Wolfe P2 
or DY breast 
patterns; age 
range, 49–65 
y; mean age, 
~55
Percent densities assigned by 
drawing and measuring a cross 
on a 100 mm line (representing 
0–100% density)
Reader 1: in the placebo and isoflavone groups 
respectively, 22% and 18% of women changed to 
a more lucent Wolfe pattern, 78% and 80% did 
not change, and 0% and 2% changed to a more 
dense Wolfe pattern. Reader 2: in the isoflavone 
and placebo groups, respectively, 15% and 19% of 
women changed to a more lucent Wolfe pattern, 
84% and 80% did not change, and 1% and 1% 
changed to a more dense Wolfe pattern. NSE of 
isoflavone treatment
Maskarinec, 
2003/(95)
15/UD
15/UD + 
tablets/76
~12 mo Healthy pre-
menopausal 
women; mean 
age, 42 y
Computer-assisted density 
assessment. Left and right 
cranio-caudal views of the 
mammograms (all free of 
malignancies) were scanned 
into a PC using a Cobrascan 
CX-612-T digitizer.
Percent breast tissue density
Control Soy
Initial 49.5 ± 12.6 34.6 ± 18.8
Final 49.9 ± 12.8 37.1 ± 16.5
Values are means ± SD. NSE
Table 1: Clinical effects of isoflavones and soy protein on markers of breast cancer risk (Continued)Nutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
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Nipple Aspirate Fluid (NAF)
Qin, 2007/
(103)
15/tablets/24
19/tablets/42
~1 mo Premenopaus
al women 
with no 
history of 
atypia, in situ 
or invasive 
breast cancer; 
age range, 19–
54; median, 
~37 y
NAF was 
collected 
before and 
after one 
menstrual 
cycle. Samples 
from the left 
and right 
breast were 
kept separate
Estrogen 
marker, 
complement 
(C)3 and cell 
cytology
NSE
Hargreaves, 
1999/(90)
53/UD
28/UD + 60 g 
soy
protein/~45
14 d Premenopaus
al women 
undergoing 
breast biopsy 
or definitive 
surgery for 
breast 
cancer;6 mean 
age, ~33 y
NAF obtained 
by bimanual, 
four-quadrant 
compression 
of the breast. 
Fluid was 
collected into 
capillary tubes, 
and the 
volume of 
neat nipple 
secretion was 
calculated by 
multiplying the 
length (in 
millimeters) of 
nipple fluid in 
the tube by 
the cross-
sectional area 
of the capillary 
tube lumen
Apolipoprotei
n D (apoD) 
and pS2 levels
Statistically significant ↑ and ↓ in pS2 and apoD 
levels, respectively (P ≤ 0.002).
Petrakis, 
1996/(102)
24/UD + 37.4 
g ISP/75
6 mo Premenpausal 
(n = 14) and 
postmenopaus
al women (N 
= 10)
NAF was 
obtained with 
a Sartorius-
type breast 
pump 
consisting of a 
15-cc syringe 
attached to a 
small cup by a 
short piece of 
plastic tubing
NAF volume, 
gross cystic 
disease fluid 
protein 
(GCDFP-15) 
concentration
, and NAF 
cytology.
Statistically significant ↑ in fluid volume and ↓ in 
GCDFP-15 in premenopausal women only. 
Epithelial hyperplasia in 7 of 24 women during 
and after ISP intake.
1 Daily isoflavone intake expressed as aglycone units; 2 ER, estrogen receptor; 3 PR, progesterone receptor; 4 NSE, no statistically significant effects; 
5 UD, usual diet; 6Women diagnosed with benign breast disease included fibroadenoma (n = 38), reduction mammoplasty (n = 10), fibrocystic 
masses (n = 9), duct ectasia (n = 6), sclerosing adenosis (n = 3), lipoma (n = 1), and accessory breast removal (n = 1); thirteen cases of breast cancer 
were of the invasive ductal type, and 3 were ductal carcinoma in situ; fourteen patients were confirmed as taking oral contraceptives at the time of 
surgery, and 61 were parous; twenty (71.4%) patients completed 13–14 days of soy supplementation, 4 (14.3%) completed 10–12 days, and 4 
(14.3%) completed 8–9 days of soy supplementation; however, all patients said they had taken the last soy tablet 24 h before surgery; 7 Details are 
described in reference; 8 ISP, isolated soy protein; 9 Isoflavones derived from red clover.
Table 1: Clinical effects of isoflavones and soy protein on markers of breast cancer risk (Continued)
cell proliferation or several other indicators of estrogenic
effect (Table 1).
Two other pilot studies involving breast cancer patients
also failed to find an effect of isoflavone supplements on
breast cell proliferation. The intervention period averaged
23 days in one study [88] and a year in the other [89]. In
both studies subjects were exposed to ≥ 100 mg isofla-
vones per day; however, the one-year study included only
9 women per group and is published only as an abstract.
Interestingly, in this study, biopsies taken from the con-
tralateral breast revealed an increase in breast cell prolifer-
ation at baseline, which supports the idea that the
"healthy" contralateral breast of breast cancer patients
may be at an increased risk of developing a tumor [94].
In addition to the lack of effect on cell proliferation, none
of the five studies conducted (three in premenopausal
[95-98], one in postmenopausal women [97] and one
involving both pre- and postmenopausal women [99])Nutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
Page 7 of 12
(page number not for citation purposes)
found that isoflavone exposure from soyfoods, ISP, or
soybean- or red clover-derived supplements significantly
affected breast tissue density (Table 1). Greater breast tis-
sue density is associated with increased breast cancer risk
and as was the case for cell proliferation, the lack of effects
of isoflavones on breast tissue density generally contrasts
with the effects of ET and EPT (see below) [100,101].
Two additional clinical trials are worthy of comment
(Table 1). In one, breast NAF was collected for a total of
one year [102]. Samples were taken over three months
prior to soy exposure, then for 6 months during which
women consumed 37.5 g ISP that provided 75 mg isofla-
vones daily, and then for 3 months after discontinuation
of soy intake [102]. Hyperplastic epithelial cells were
noted in 7 of 24 (29.2%) women (4 premenopausal and
3 postmenopausal) while consuming soy whereas prior to
soy consumption hyperplastic cells were noted in only 1
of 24 women (4.2%) [102]. The authors concluded that
these findings suggest that soybean isoflavones exert an
estrogenic stimulus on breast tissue. However, it is impor-
tant to point out that this was a pilot study with several
limitations including the lack of a control group, a high
dropout rate (only 15 of 37 subjects finished the 12-
month regimen), and the fact that hyperplastic epithelial
cells in the NAF persisted far beyond cessation of soy pro-
tein intake. Furthermore, a more recent study involving 34
premenopausal women found that isoflavones had no
impact on breast cell cytology after one month exposure
to either ~24 or 42 mg/d isoflavones [103]. While the
available trials examining breast proliferation and density
have found no statistically significant effects of isofla-
vone-containing products it is important to recognize that
many of these studies involved small sample sizes or were
relative short in duration.
Finally, two epidemiologic studies were identified that
examined the relationship between soy or isoflavone
intake and breast cancer survival. The first found that soy-
food intake was unrelated to survival over the 5.2 year fol-
low-up period [104]. In this study, approximately 63% of
the 1001 Chinese breast cancer cases (out of 1459 subjects
in the total cohort) for whom data on receptor status was
available were ER+. In the other study, when comparing
the fifth versus the first intake quintiles, isoflavone intake
was associated with a reduced risk of all-cause mortality
over the approximate 5-year follow-up period [105]. Iso-
flavone intake was also associated with a marginal reduc-
tion in risk of breast cancer-specific mortality, although
the effect was not statistically significant. Of note, the iso-
flavone intake cutoffs for the fifth quintile were only 7.48
and 0.60 mg/d for all-cause and breast cancer-specific
mortality, respectively, and the percentage of ER+ patients
among the 1210 subjects was not indicated.
Estrogen and breast cancer risk
Since the estrogen-like effects of isoflavones are at the core
of the soy-breast cancer controversy, understanding the
relationship between estrogen and breast cancer provides
a potentially useful perspective. There is a large amount of
evidence that endogenous estrogens are involved in the
etiology of certain types of breast cancer [106,107].
Endogenous estrogens increase breast epithelial prolifera-
tion and may facilitate growth of estrogen-sensitive neo-
plastic or preneoplastic cells [108,109]. Many of the
major epidemiologic risk factors for breast cancer also
relate to endogenous estrogen exposure. For example,
greater lifelong exposure to ovarian estrogen – as occurs
with early menarche and late menopause – is associated
with increased breast cancer risk [110-112], whereas
oophorectomy reduces risk in premenopausal women
[113-115]. In postmenopausal women, higher endog-
enous circulating concentrations of estrogen [116,117]
are associated with increased risk, as are obesity and alco-
hol intake, both of which result in higher endogenous
estrogen levels [112,118]. Conversely, treatment with
tamoxifen and raloxifene, which inhibits ER activity in the
breast, and aromatase inhibitors, which reduce endog-
enous estrogen production, are effective for treating and
preventing ER+ breast cancer [119,120].
The risk of breast cancer associated with exogenous estro-
gen exposure is less clear, however, due in part to recent
results of the Women's Health Initiative (WHI). This study
consisted of two large parallel randomized, double-blind,
placebo-controlled clinical trials of hormone therapy
designed to evaluate effects of conjugated equine estro-
gens (CEE) alone (for women with prior hysterectomy) or
in combination with the progestin medroxyprogesterone
acetate (MPA). In the WHI Estrogen + Progestin Trial, use
of CEE + MPA led to a 26% increase in breast cancer risk
(38 vs 30 cases per 10,000 person-years) which was highly
significant in the weighted analysis (P < 0.001) [121].
However, in the WHI Estrogen-Alone Trial, after an aver-
age of 7.1 years of follow-up, women assigned to CEE
alone at 0.625 mg/d were 18% less likely to develop inva-
sive breast cancer compared to women in the placebo
group (26 vs 33 cases per 10,000 person-years; P = 0.09)
[122]. When the latter analysis was restricted to adherent
subjects, risk in the CEE group was reduced by one-third
(P = 0.03), while the incidence of localized breast carci-
noma and ductal carcinoma were lower by 31% and 29%,
respectively [123].
The reason for the marginal reduction in breast cancer risk
associated with estrogen-alone therapy in the WHI trial is
currently unknown. Prior epidemiologic evidence regard-
ing ET effects on breast cancer risk is mixed but generally
indicates either no significant effect or a modest increase
in risk with long-term exposure [124-128]. VariationNutrition Journal 2008, 7:17 http://www.nutritionj.com/content/7/1/17
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within and across observational studies may relate to a
variety of factors, including subject selection, screening
frequency, duration of hormone use, hormone formula-
tions and doses, and patient characteristics such as repro-
ductive history, body mass index, and background
endogenous estrogen context. Nevertheless, overall risks
from observational studies are generally small for ET and
notably lower than those reported for combined EPT, con-
sistent with WHI results. Importantly, studies of ET use in
breast cancer survivors (generally for periods < 5–10
years) also indicate minimal if any risk for recurrence or
mortality [129-135].
Direct effects of ET (CEE in particular) on breast prolifer-
ation and density are generally modest and less than those
seen with EPT. In one of the few clinical studies to assess
breast proliferation following ET and EPT, postmenopau-
sal women taking EPT but not ET had significantly greater
breast epithelial Ki67 expression in terminal ductal lobu-
lar areas [82]. In this study, ET was associated with mod-
estly higher percent breast epithelial area (~15%)
compared to the control group (~7%; P = 0.01), while EPT
resulted in greater density beyond that seen with ET
(~24%; P = 0.02 compared to ET).
Consistent with these findings, the Postmenopausal
Estrogen/Progestin Interventions (PEPI) randomized pla-
cebo-controlled clinical trial reported a non-significant
change in mammographic density of +1.2% after 1 year of
CEE treatment compared to significant increases of +3.1
to +4.8% for different EPT regimens [136]. In the WHI,
absolute changes in mammographic density were not
reported, although CEE resulted in a greater overall per-
centage of women with abnormal mammograms (36.2%
for CEE compared to 28.1% for placebo) [123].
In conclusion, while there is general agreement that
endogenous estrogen exposure has an important role in
the etiology of breast cancer, the extent to which postmen-
opausal exogenous estrogen exposure affects risk is much
less certain. Current evidence suggests that use of oral ET
(particularly CEE) by relatively healthy postmenopausal
women for periods < 10 years has very low if any risk for
breast cancer and minimal to no effect on breast cancer
recurrence or mortality in breast cancer survivors. This
information provides a sensible context for considering
the potential adverse effects on dietary soyfoods or isofla-
vones. Given the low overall risk associated with pharma-
cologic estrogen exposure, how reasonable is it to expect
that any weak estrogen-like effects of soy-derived isofla-
vones (which have yet to be clearly demonstrated in the
breast) may increase breast cancer risk or worsen the prog-
nosis of breast cancer patients?
Summary and conclusion
Isoflavones are phytoestrogens which interact with ERs
and generally function as weak estrogens in rodent and
cell culture models. These estrogen-like effects have raised
concern regarding soy/isoflavone consumption, particu-
larly in the case of postmenopausal women at high risk for
breast cancer. Currently there is little evidence to suggest
that any potential weak estrogenic effects of dietary isofla-
vones have a clinically relevant impact on breast tissue in
healthy women. Limited data suggest this is also the case
for breast cancer survivors. This evidence includes multi-
ple trials showing no effects on breast proliferation or
mammographic density and considerable epidemiologic
data showing either no effect or a modest protective role
of soy/isoflavone intake on breast cancer risk. Tangential
support for this idea is also provided by recent clinical
trial findings regarding exogenous ET (in the form of CEE)
showing a marginal decrease in risk of invasive breast can-
cer. Based on this evidence it seems unlikely that isofla-
vone consumption at dietary levels (i.e. <100 mg/day)
elicits adverse breast cancer-promoting effects in healthy
women or breast cancer survivors not undergoing active
treatment. Findings from one rodent study showed that
genistein may interfere with concurrent tamoxifen treat-
ment, suggesting that breast cancer patients taking a SERM
may need to limit soyfood intake and avoid isoflavone
supplements. Currently there are no data to support the
idea that soyfoods or isoflavone supplements improve the
prognosis of breast cancer patients. Available data for ET
effects on breast cancer recurrence and mortality provide
some assurance for breast cancer patients that soyfoods/
isoflavone supplements, when taken at dietary levels, do
not contribute to recurrence rates although more data are
clearly needed to better address this issue.
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